Targeted therapy in Multiple Myeloma: Results of first phase I study with everolimus (RAD001)

被引：0
|
作者：
Guenther, A. [1 ]
Baumann, P. [2 ]
Burger, R. [1 ]
Klapper, W. [3 ]
Schmidmaier, R. [2 ]
Gramatzki, M. [1 ]
机构：
[1] UKSH Campus Kiel, Med Klin 2, Sekt Stammzell & Immuntherapie, Kiel, Germany
[2] Klinikum Univ Munchen, Med Klin Innenstadt, Munich, Germany
[3] UKSH Campus Kiel, Inst Pathol, Sekt Hamatopathol, Kiel, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [1] Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Kellner, Christian
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    HAEMATOLOGICA, 2015, 100 (04) : 544 - 550
  • [2] Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study
    Guenther, A.
    Baumann, P.
    Burger, R.
    Klapper, W.
    Schmidmaier, R.
    Gramatzki, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma.
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    BLOOD, 2009, 114 (22) : 1481 - 1481
  • [4] Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors
    Chan, Jennifer A.
    Ryan, David P.
    Zhu, Andrew X.
    Abrams, Thomas A.
    Wolpin, Brian M.
    Malinowski, Paige
    Regan, Eileen M.
    Fuchs, Charles S.
    Kulke, Matthew H.
    ENDOCRINE-RELATED CANCER, 2012, 19 (05) : 615 - 623
  • [5] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Jennifer A. Chan
    Robert J. Mayer
    Nadine Jackson
    Paige Malinowski
    Eileen Regan
    Matthew H. Kulke
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1241 - 1246
  • [6] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Chan, Jennifer A.
    Mayer, Robert J.
    Jackson, Nadine
    Malinowski, Paige
    Regan, Eileen
    Kulke, Matthew H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1241 - 1246
  • [7] Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis
    Mahindra, Anuj
    Richardson, Paul G.
    Hari, Parameswaran
    Sohani, Aliyah R.
    Laubach, Jacob P.
    Burke, Jill
    Kaster, Sarah
    Connolly, Christine
    Rivera, Linda
    Jacobs, Paulette
    Saad, Ayman
    Colson, Kathleen
    Ghobrial, Irene
    Schlossman, Robert L.
    Adams, Jennifer
    Makrides, Wendy
    Weller, Edie
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Raje, Noopur
    BLOOD, 2010, 116 (21) : 1258 - 1258
  • [8] Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple mycloma
    Mahindra, A. K.
    Richardson, P. G.
    Hari, P.
    Laubach, J.
    Ghobrial, I. M.
    Schlossman, R. L.
    Weller, E.
    Munshi, N. C.
    Anderson, K. C.
    Raje, N. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo
    Mitsiades, N
    McMullan, C
    Poulaki, V
    Negri, J
    Raje, N
    Kumar, S
    Sikoutri, D
    Hideshima, T
    Chauhan, D
    Richardson, PG
    Schlossman, RL
    Kung, AL
    Lane, H
    Munshi, NC
    Anderson, KC
    Mitsiades, CS
    BLOOD, 2004, 104 (11) : 418A - 418A
  • [10] Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC)
    Sharma, S.
    Reid, T.
    Hoosen, S.
    Garrett, C.
    Beck, J.
    Davidson, S.
    MacKenzie, M.
    Brandt, U.
    Hecht, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345